Amgen Inc. (NASDAQ:AMGN) Shares Sold by Triasima Portfolio Management inc.

Triasima Portfolio Management inc. lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 62.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,244 shares of the medical research company's stock after selling 7,138 shares during the quarter. Triasima Portfolio Management inc.'s holdings in Amgen were worth $1,106,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in Amgen during the third quarter worth $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the 3rd quarter worth about $29,000. Matrix Trust Co purchased a new position in Amgen during the 3rd quarter valued at about $36,000. Heck Capital Advisors LLC acquired a new position in Amgen in the 4th quarter valued at about $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in Amgen during the third quarter worth about $56,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

AMGN traded up $1.25 during trading on Monday, reaching $294.79. 2,375,450 shares of the stock were exchanged, compared to its average volume of 3,280,951. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market capitalization of $158.46 billion, a price-to-earnings ratio of 39.05, a P/E/G ratio of 3.01 and a beta of 0.56. The business's 50 day moving average price is $272.26 and its two-hundred day moving average price is $302.77. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities research analysts anticipate that Amgen Inc. will post 20.59 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen's previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.23%. Amgen's payout ratio is presently 119.21%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.69% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Redburn Partners dropped their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Citigroup reduced their price objective on shares of Amgen from $310.00 to $295.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Piper Sandler boosted their target price on shares of Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research note on Monday. Finally, StockNews.com cut Amgen from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $314.09.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.